journal
MENU ▼
Read by QxMD icon Read
search

European Heart Journal. Cardiovascular Pharmacotherapy

journal
https://www.readbyqxmd.com/read/29982385/new-potassium-binders-reduce-the-risk-of-hyperkalaemia-in-patients-treated-with-renin-angiotensin-aldosterone-system-inhibitors
#1
Maria Tamargo, Juan Tamargo
No abstract text is available yet for this article.
July 2, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29945162/safety-and-effectiveness-of-rivaroxaban-and-apixaban-in-patients-with-venous-thromboembolism-a-nationwide-study
#2
Caroline Sindet-Pedersen, Laila Staerk, Jannik Langtved Pallisgaard, Thomas Alexander Gerds, Jeffrey S Berger, Christian Torp-Pedersen, Gunnar H Gislason, Jonas Bjerring Olesen
Aim: To investigate the risk of all-cause mortality, recurrent VTE, and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban. Methods and results: Using Danish nationwide registries, patients with VTE treated with rivaroxaban or apixaban in the period from January 1st 2015 to June 30th 2017 were identified. Standardized absolute risks were estimated based on outcome-specific Cox regression models, adjusted for potential confounders...
June 26, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29878086/adherence-to-dual-antiplatelet-therapy-with-ticagrelor-in-patients-with-acute-coronary-syndromes-treated-with-percutaneous-coronary-intervention-in-real-life-results-of-the-real-tica-registry
#3
Uwe Zeymer, Martin Cully, Mathias Hochadel
Aims: Little is known about the adherence to dual antiplatelet therapy with ticagrelor and reasons for discontinuation in real ife. Therefore we evaluated the 12-month course of patients with acute coronary syndromes (ACS) treated with percutaneous coronary intervention (PCI) and ticagrelor during the acute phase. Methods and results: A total of 614 patients included into the prospective ALKK-PCI Registry between 2014 and 2015 surviving for at least 12 months after discharge provided informations about duration of ticagrelor therapy...
June 7, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29846559/early-occurrence-of-drug-intolerance-as-risk-factor-during-follow-up-in-patients-with-acute-coronary-syndrome-or-coronary-revascularization
#4
Stefano Albani, Enrico Fabris, Sara Doimo, Giulia Barbati, Andrea Perkan, Marco Merlo, Giuseppe Gatti, Andrea Di Lenarda, Arnoud Van't Hof, Patrizia Maras, Gianfranco Sinagra
Aims: The occurrence of drug intolerance (DI) after an acute coronary syndrome (ACS) or percutaneous coronary revascularization (PCI) is an important reason for quitting treatment. Nevertheless, the association between DI and major cardiac and cerebrovascular events (MACCE) is poorly reported in literature, therefore we analysed potential relationship between DI and MACCE (a composite of ACS, PCI, heart failure, stroke) during follow-up. Methods and Results: From 1/1/2014 to 31/12/2015, 891 consecutive patients after ACS or coronary revascularization were referred to Cardiac Rehabilitation (CR) Program and included in a dedicated registry where DI was analysed and treatment appropriately tailored...
May 29, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29726985/expert-consensus-document-on-the-management-of-hyperkalaemia-in-patients-with-cardiovascular-disease-treated-with-renin-angiotensin-aldosterone-system-inhibitors-coordinated-by-the-working-group-on-cardiovascular-pharmacotherapy-of-the-european-society-of-cardiology
#5
Giuseppe M C Rosano, Juan Tamargo, Keld P Kjeldsen, Mitja Lainscak, Stefan Agewall, Stefan D Anker, Claudio Ceconi, Andrew J S Coats, Heinz Drexel, Gerasimos Filippatos, Juan Carlos Kaski, Lars Lund, Alexander Niessner, Piotr Ponikowski, Gianluigi Savarese, Thomas A Schmidt, Petar Seferovic, Sven Wassmann, Thomas Walther, Basil S Lewis
Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard endpoints. Renin angiotensin aldosterone system inhibitors are also the basis in treatment of arterial hypertension, and they are furthermore indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease, where they have specific indication because of the evidence of benefit...
July 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29554294/cardiovascular-pharmacotherapy-and-real-world-data
#6
Stefan Agewall
No abstract text is available yet for this article.
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29554293/how-does-the-trs-2%C3%A2-p-score-relate-to-real-world-patients
#7
Marc P Bonaca, Gaetano M De Ferrari, Dan Atar, Lori D Bash, Dominik Lautsch, Erin A Bohula, Martin Horack, Philippe Brudi, Jean Ferrieres, Anselm K Gitt
No abstract text is available yet for this article.
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29554292/trimetazidine-is-there-a-role-beyond-angina
#8
Jason M Tarkin, Juan Carlos Kaski
No abstract text is available yet for this article.
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29394340/trends-in-optimal-medical-therapy-prescription-and-mortality-after-admission-for-acute-coronary-syndrome-a-9-year-experience-in-a-real-world-setting
#9
Niels P G Hoedemaker, Peter Damman, Jan Paul Ottervanger, Jan Henk E Dambrink, A T Marcel Gosselink, Elvin Kedhi, Evelien Kolkman, Robbert J de Winter, Arnoud W J van 't Hof
Aims: Optimal medical therapy (OMT) is recommended in acute coronary syndrome (ACS) patients. Few studies present temporal trends of OMT prescription and its impact on outcomes in a real-world setting. We aimed to evaluate OMT prescription in a real-world ACS population and its relation to mortality during almost a decade. Methods and results: Consecutive ST-elevation myocardial infarction and non-ST-elevation myocardial infarction (NSTEMI) patients (n = 9202) admitted to a single Dutch tertiary hospital between 2006 and 2014 were included and followed for drug prescription and mortality up to 1 year...
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29385429/antithrombotic-therapy-use-and-clinical-outcomes-following-thrombo-embolic-events-in-patients-with-atrial-fibrillation-insights-from-aristotle
#10
Shinya Goto, Peter Merrill, Lars Wallentin, Daniel M Wojdyla, Michael Hanna, Alvaro Avezum, J Donald Easton, Veli-Pekka Harjola, Kurt Huber, Basil S Lewis, Alexander Parkhomenko, Jun Zhu, Christopher B Granger, Renato D Lopes, John H Alexander
Aims: We investigated baseline characteristics, antithrombotic use, and clinical outcomes of patients with atrial fibrillation (AF) and a thrombo-embolic event in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study to better inform the care of these high-risk patients. Method and results: Thrombo-embolic events were defined as stroke (ischaemic or unknown cause) or systemic embolism (SE). Clinical outcomes were estimated using the Kaplan-Meier method...
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29272379/annual-adverse-event-profiles-after-clopidogrel-prasugrel-and-ticagrelor-in-the-food-and-drug-administration-adverse-event-reporting-system
#11
Vasily Cherepanov, Seth D Fortmann, Moo Hyun Kim, Thomas A Marciniak, Oleg Litvinov, Kyryl Mihalev, Victor L Serebruany
No abstract text is available yet for this article.
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29194462/new-strategies-for-the-development-of-lipid-lowering-therapies-to-reduce-cardiovascular-risk
#12
Ian Graham, Chuck Shear, Pieter De Graeff, Caroline Boulton, Alberico L Catapano, Wendy Gattis Stough, Stefan C Carlsson, Guy De Backer, Joseph Emmerich, Scott Greenfeder, Albert M Kim, Dominik Lautsch, Tu Nguyen, Steven E Nissen, Krishna Prasad, Kausik K Ray, Jennifer G Robinson, William J Sasiela, Karsten Bruins Slot, Erik Stroes, Tom Thuren, Bart Van der Schueren, Maja Velkovski-Rouyer, Scott M Wasserman, Olov Wiklund, Emmanouil Zouridakis
The very high occurrence of cardiovascular events presents a major public health issue, because treatment remains suboptimal. Lowering LDL cholesterol (LDL-C) with statins or ezetimibe in combination with a statin reduces major adverse cardiovascular events. The cardiovascular risk reduction in relation to the absolute LDL-C reduction is linear for most interventions without evidence of attenuation or increase in risk at low LDL-C levels. Opportunities for innovation in dyslipidaemia treatment should address the substantial risk of lipid-associated cardiovascular events among patients optimally treated per guidelines but who cannot achieve LDL-C goals and who could benefit from additional LDL-C-lowering therapy or experience side effects of statins...
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29106501/corrigendum-to-changes-in-oral-anticoagulation-for-elective-cardioversion-results-from-a-european-cardioversion-registry
#13
(no author information available yet)
No abstract text is available yet for this article.
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/28950374/non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-atrial-fibrillation-and-valvular-heart-disease-systematic-review-and-meta-analysis
#14
Daniel Caldeira, Cláudio David, João Costa, Joaquim J Ferreira, Fausto J Pinto
The non-vitamin K antagonist oral anticoagulants (NOACs) were approved for non-valvular atrial fibrillation (AF) but this term may be misnomer. Thus, the term non-mechanical and rheumatic mitral valvular (non-MARM) AF was proposed to exclude patients with valvular heart disease (VHD) without contraindications for NOACs. We aimed to review the efficacy and safety of NOACs in patients with AF and VHD compared to Vitamin K Antagonists (VKA). We performed a systematic review with meta-analysis (PROSPERO CRD42015024837) including data from randomized controlled trials (RCTs) retrieved in November 2016...
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/28510644/temporal-trends-in-acute-myocardial-infarction-presentation-and-association-with-use-of-cardioprotective-drugs-a-nationwide-registry-based-study
#15
Laerke Smedegaard, Mette Gitz Charlot, Gunnar Hilmar Gislason, Peter Riis Hansen
Aim: The present study aimed to investigate temporal trends in myocardial infarction (MI) presentation with or without ST-segment elevation and the association with the use of cardioprotective drugs prior to admission. Methods and results: Using individual-level linkage of data from Danish nationwide registries, we identified all patients 30 years or older admitted with a first-time MI in the period 2003-2012, and their use of cardioprotective drugs 6 months prior to admission...
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/28475676/comparative-effectiveness-of-enalapril-lisinopril-and-ramipril-in-the-treatment-of-patients-with-chronic-heart-failure-a-propensity-score-matched-cohort-study
#16
Hanna Fröhlich, Felix Henning, Tobias Täger, Dieter Schellberg, Morten Grundtvig, Kevin Goode, Anna Corletto, Syed Kazmi, Torstein Hole, Hugo A Katus, Dan Atar, John G F Cleland, Stefan Agewall, Lutz Frankenstein, Andrew L Clark
Aims: Angiotensin-converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known. Methods and results: A total of 4723 outpatients with stable HFrEF prescribed enalapril, lisinopril, or ramipril were identified from three registries in Norway, England, and Germany. In three separate matching procedures, patients were individually matched with respect to both dose equivalents and their respective propensity scores for ACEI treatment...
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/27773877/erratum-to-sglt1-does-compensate-for-sglt2-inhibition
#17
(no author information available yet)
No abstract text is available yet for this article.
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29562254/corrigendum
#18
(no author information available yet)
No abstract text is available yet for this article.
March 19, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29528386/preadmission-use-of-platelet-inhibitors-and-short-term-stroke-mortality-a-population-based-cohort-study
#19
Morten Würtz, Morten Schmidt, Erik Lerkevang Grove, Erzsébet Horváth-Puhó, Victor W Henderson, Christian Fynbo Christiansen, Henrik Toft Sørensen
Aims: The impact of preadmission antiplatelet treatment on prognosis after stroke is poorly understood. We therefore investigated whether preadmission use of aspirin and clopidogrel was associated with mortality in patients hospitalized with ischemic stroke, intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SAH). Methods and Results: We used nationwide population-based registries to identify all first-time hospitalizations for stroke and subsequent mortality in patients treated with aspirin and clopidogrel in Denmark during 2004-2012...
March 8, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29514184/the-quality-of-warfarin-therapy-and-cha2ds2-vasc-score-associate-with-the-incidence-of-myocardial-infarction-and-cardiovascular-outcome-in-patients-with-atrial-fibrillation-data-from-the-nationwide-finwaf-registry
#20
M J Pekka Raatikainen, Tero Penttilä, Pasi Korhonen, Juha Mehtälä, Riitta Lassila, Mika Lehto
Aims: The impact of the quality of warfarin therapy on cardiovascular outcomes excluding stroke is largely unknown. The aims of this study were to evaluate the association between the warfarin control and the incidence and outcome of myocardial infarction (MI), and to validate the predictive value of the CHA2DS2-VASc score for MI in AF patients taking warfarin. Methods and Results: The nationwide FinWAF registry consists of 54568 AF patients (mean age 73.1±10...
March 5, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
journal
journal
53372
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"